Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in:

13-11-2024 | Chronic Inflammatory Bowel Disease | Review

Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians

Authors: Natasha Klemm, Sarvee Moosavi

Published in: Digestive Diseases and Sciences | Issue 12/2024

Login to get access

Abstract

Inflammatory bowel disease (IBD) is a chronic condition that includes ulcerative colitis and Crohn’s disease. It is characterized by a relapsing and remitting pattern that negatively impacts quality of life (QoL). Current goals of treatment involve symptomatic, biochemical, and endoscopic remission in a treat-to-target approach. Despite effective treatment and remission of IBD, many patients report frequent and isolated abdominal pain. A wide range of etiologies exist, including surgery-related, infections, pelvic conditions, immune-related, and systemic illnesses. Disorders of the gut–brain interaction (DGBI), frequently characterized by abdominal pain, are increasingly recognized in IBD patients, including those with quiescent disease. Various mechanisms are involved and numerous non-pharmacologic and pharmacologic therapies have been proposed. Hereby, we outline the pertinent findings of the literature on management of chronic abdominal pain, focusing on quiescent IBD.
Literature
1.
Coates MD, Johri A, Gorrepati VS et al. Abdominal pain in quiescent inflammatory bowel disease. Int J Colorectal Dis 2021;36:93–102.PubMed
2.
Nicholas M, Vlaeyen JWS, Rief W et al. The IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic primary pain. Pain 2019;160:28–37.PubMed
3.
Drewes AM, Olesen AE, Farmer AD et al. Gastrointestinal pain. Nat Rev Dis Primers 2020;6:1.PubMed
4.
Dunleavy KA, Cross RK, Raffals LE. Causes, diagnostic testing, and treatment of residual symptoms in patients with IBD with quiescent disease. Am J Gastroenterol 2023;118:1909–1914.PubMed
5.
6.
Coates MD, Clarke K, Williams E et al. Abdominal pain in inflammatory bowel disease: an evidence-based, multidisciplinary review. Crohn’s Colitis 360 2023;5:1–18.
7.
Shah A, Morrison M, Burger D et al. Systematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Aliment Pharmacol Ther 2018;49:624–635.
8.
Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012;107:1474–1482.PubMed
9.
Fairbrass KM, Costantino SJ, Gracie DJ, Ford AC. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:1053–1062.PubMed
10.
Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain–gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol 2019;4:632–642.PubMed
11.
12.
Abdalla MII, Sandler RS, Kappelman MD et al. Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners. Inflamm Bowel Dis 2017;23:325–331.PubMed
13.
Bosman MHMA, Weerts ZZRM, Snijkers JTW et al. The socioeconomic impact of irritable bowel syndrome: an analysis of direct and indirect health care costs. Clin Gastroenterol Hepatol 2023;21:2660–2669.PubMed
14.
Kuenzig ME, Im JHB, Coward S et al. The 2023 impact of inflammatory bowel disease in Canada: indirect (individual and societal) and direct out-of-pocket costs. J Can Assoc Gastroenterol 2023;6:S16–S22.PubMedPubMedCentral
15.
Bogale K, Maheshwari P, Kang M et al. Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease. Sci Rep 2022;12:1–8.
16.
17.
Gregor JC, Williamson M, Dajnowiec D, Sattin B, Sabot E, Salh B. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adherence 2018;12:505–513.PubMedPubMedCentral
18.
Louis E, Siegel CA, James B, Heidenreich S, Krucien N, Ghosh S. Patients with inflammatory bowel disease have heterogeneous treatment preferences that are largely determined by the avoidance of abdominal pain and side effects [P-POWER IBD Study]. J Crohn’s Colitis 2023;17:231–239.
19.
Balbale SN, Iroz CB, Schäfer WLA, Johnson JK, Stulberg JJ. A missing piece of the puzzle: patient and provider perspectives on pain management needs and opioid prescribing in inflammatory bowel disease care. Crohn’s Colitis 2022;360:1–15.
20.
Weaver E, Szigethy E. Managing pain and psychosocial care in IBD: a primer for the practicing gastroenterologist. Curr Gastroenterol Rep 2020;22:20.PubMed
21.
Colombel JF, Shin A, Gibson PR. AGA clinical practice update on functional gastrointestinal symptoms in patients with inflammatory bowel disease: expert review. Clin Gastroenterol Hepatol 2019;17:380-390.e1.PubMed
22.
Quigley EMM. Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye? Ther Adv Gastroenterol 2016;9:199–212.
23.
Lacy BE, Pimentel M, Brenner DM et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 2020;116:17–44.
24.
Vasant DH, Paine PA, Black CJ et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 2021;70:1–27.
25.
Le Zhan Y, An Zhan Y, Xue Dai S. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. Clin Nutr 2018;37:123–129.PubMed
26.
Pedersen N, Ankersen DV, Felding M et al. Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World J Gastroenterol 2017;23:3356–3366.PubMedPubMedCentral
27.
Grammatikopoulou MG, Goulis DG, Gkiouras K et al. Low FODMAP diet for functional gastrointestinal symptoms in quiescent inflammatory bowel disease: a systematic review of randomized controlled trials. Nutrients 2020;12:1–22.
28.
Melgaard D, Sørensen J, Riis J et al. Efficacy of FODMAP elimination and subsequent blinded placebo-controlled provocations in a randomised controlled study in patients with ulcerative colitis in remission and symptoms of irritable bowel syndrome: a feasibility study. Nutrients 2022;14:4–7.
29.
Gu B, Yu Z, Shi C, Yan C, Chen B, Zhou J. Effects of low-FODMAP diet on irritable bowel symptoms in patients with quiescent inflammatory bowel disease. Medicine (United States) 2022;101:4–7.
30.
Lewis JD, Sandler RS, Brotherton C et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn’s disease. Gastroenterology 2021;161:837-852.e9.PubMed
31.
32.
Robelin K, Senada P, Ghoz H et al. Prevalence and clinician recognition of avoidant/restrictive food intake disorder in patients with inflammatory bowel disease. Gastroenterol Hepatol 2021;17:510–514.
33.
Yelencich E, Truong E, Widaman AM et al. Avoidant restrictive food intake disorder prevalent among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2022;20:1282-1289.e1.PubMed
34.
Bianco A, Russo F, Franco I et al. Enhanced physical capacity and gastrointestinal symptom improvement in southern Italian IBS patients following three months of moderate aerobic exercise. J Clin Med 2023;12:6786.PubMedPubMedCentral
35.
Zhou C, Zhao E, Li Y, Jia Y, Li F. Exercise therapy of patients with irritable bowel syndrome: a systematic review of randomized controlled trials. Neurogastroenterol Motil 2019;31:1–10.
36.
37.
38.
D’Silva A, Marshall DA, Vallance JK et al. Meditation and yoga for irritable bowel syndrome: a randomized clinical trial. Am J Gastroenterol 2023;118:329–337.PubMed
39.
Nunan D, Cai T, Gardener A, et al. Physical activity for treatment of irritable bowel syndrome: summary of a Cochrane Review. Explore 2023;19:774–775.
40.
D’Silva A, Marshall DA, Vallance JK et al. Gastroenterologist and patient attitudes toward yoga as a therapy for irritable bowel syndrome: an application of the theory of planned behaviour. J Can Assoc Gastroenterol 2023;6:17–25.PubMed
41.
Davis SP, Crane PB, Bolin LP, Johnson LA. An integrative review of physical activity in adults with inflammatory bowel disease. Intest Res 2022;20:43–52.PubMed
42.
Mareschal J, Douissard J, Genton L. Physical activity in inflammatory bowel disease: benefits, challenges and perspectives. Curr Opin Clin Nutr Metab Care 2022;25:159–166.PubMed
43.
Oketola B, Akinrolie O, Webber S et al. Physical activity for quiescent and mildly active inflammatory bowel disease: a systematic review and meta-analysis. J Can Assoc Gastroenterol 2023;6:162–171.PubMedPubMedCentral
44.
Sinopoulou V, Gordon M, Dovey TM, Akobeng AK. Interventions for the management of abdominal pain in ulcerative colitis. Cochrane Database Syst Rev 2021;7:CD013589.PubMed
45.
Sinopoulou V, Gordon M, Akobeng AK et al. Interventions for the management of abdominal pain in Crohn’s disease and inflammatory bowel disease. Cochrane Database Syst Rev 2021;11:CD013531.PubMed
46.
Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome. Am J Gastroenterol 2019;114:21–39.PubMed
47.
Ballou S, Keefer L. Psychological interventions for irritable bowel syndrome and inflammatory bowel diseases. Clin Transl Gastroenterol 2017;8:e214.PubMedPubMedCentral
48.
Everitt HA, Landau S, Reilly GO et al. Assessing telephone-delivered cognitive–behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut 2019;68:1613–1623.PubMed
49.
Chen J, Chen X, Sun Y et al. The physiological and psychological effects of cognitive behavior therapy on patients with inflammatory bowel disease before COVID-19: a systematic review. BMC Gastroenterol 2021;21:1–11.
50.
Zia JK, Lenhart A, Yang P et al. Risk factors for abdominal pain-related disorders of gut–brain interaction in adults and children: a systematic review. Gastroenterology 2022;163:995-1023.e3.PubMed
51.
Liu M, Ye Z, Wu Q et al. Healthy sleep, mental health, genetic susceptibility, and risk of irritable bowel syndrome. J Affect Disord 2023;331:25–32.PubMed
52.
Salwen-Deremer JK, Siegel CA, Smith MT. Cognitive behavioral therapy for insomnia: a promising treatment for insomnia, pain, and depression in patients with IBD. Crohn’s Colitis 2020;360:1–8.
53.
Hunt MG, Loftus P, Accardo M, Keenan M, Cohen L, Osterman MT. Self-help cognitive behavioral therapy improves health-related quality of life for inflammatory bowel disease patients: a randomized controlled effectiveness trial. J Clin Psychol Med Settings 2020;27:467–479.PubMed
54.
Sweeney L, Moss-Morris R, Czuber-Dochan W, Norton C. Pain management in inflammatory bowel disease: feasibility of an online therapist-supported CBT-based self-management intervention. Pilot Feasibility Stud 2021;7:1–15.
55.
Barnes A, Mountifield R, Baker J, Spizzo P, Bampton P, Mukherjee S. Systematic review and meta-analysis of sleep quality in inactive inflammatory bowel disease. JGH Open 2022;6:738–744.PubMedPubMedCentral
56.
Hood MM, Jedel S. Mindfulness-based interventions in inflammatory bowel disease. Gastroenterol Clin N Am 2017;46:859–874.
57.
Berrill JW, Sadlier M, Hood K, Green JT. Mindfulness-based therapy for inflammatory bowel disease patients with functional abdominal symptoms or high perceived stress levels. J Crohn’s Colitis 2014;8:945–955.
58.
Ewais T, Begun J, Kenny M et al. A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease. J Psychosom Res 2019;116:44–53.PubMed
59.
Elkins GR, Barabasz AF, Council JR, Spiegel D. Advancing research and practice: the Revised APA Division 30 Definition of Hypnosis. Am J Clin Hypn 2015;57:378–385.PubMed
60.
Szigethy E. Hypnotherapy for inflammatory bowel disease across the lifespan. Am J Clin Hypn 2015;58:81–99.PubMed
61.
Peters SL, Muir JG, Gibson PR. Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1104–1115.PubMed
62.
Hoekman DR, Vlieger AM, Stokkers PC et al. Hypnotherapy for irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease: a randomized, controlled trial. J Crohn’s Colitis 2021;15:1106–1113.
63.
Weerts ZZRM, Masclee AAM, Witteman BJM et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology 2020;2020:123–136.
64.
Nee J, Ballou S, Kelley J et al. Peppermint oil treatment for irritable bowel syndrome: a randomized placebo-controlled trial. Am J Gastroenterol 2021;116:2279–2285.PubMed
65.
Shi Y, Tao Q, Qin D, Chen M, Yu S, Zheng H. Acupuncture vs. antispasmodics in the treatment of irritable bowel syndrome: an adjusted indirect treatment comparison meta-analysis. Front Physiol 2022;13:1–11.
66.
Yang Y, Wang J, Zhang C et al. The efficacy and neural mechanism of acupuncture therapy in the treatment of visceral hypersensitivity in irritable bowel syndrome. Front Neurosci 2023;17:1251470.PubMedPubMedCentral
67.
Yaklai K, Pattanakuhar S, Chattipakorn N, Chattipakorn SC. The role of acupuncture on the gut–brain–microbiota axis in irritable bowel syndrome. Am J Chin Med 2021;49:285–314.PubMed
68.
Bao C, Wu L, Wang D et al. Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn’s disease: a randomized controlled trial. EClinicalMedicine 2022;45:1–14.
69.
Wang X, Zhao N, Sun Y et al. Acupuncture for ulcerative colitis: a systematic review and meta-analysis of randomized clinical trials. BMC Complement Med Ther 2020;20:309.PubMedPubMedCentral
70.
Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology 2022;163:137–151.PubMed
71.
Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, Gutiérrez-Udave R, Maldonado-Garza HJ, Bosques-Padilla FJ. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex 2012;77:82–90.PubMed
72.
Brenner DM, Lacy BE. Antispasmodics for chronic abdominal pain: analysis of North American treatment options. Am J Gastroenterol 2021;116:1587–1600.PubMedPubMedCentral
73.
Zheng L, Lu W, Xiao Q et al. Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial. Sci Rep 2021;11:1–13.
74.
Rahimi R, Nikfar S, Rezale A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009;15:1548–1553.PubMedPubMedCentral
75.
Qun Chao G, Zhang S. A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Intern Med 2013;52:419–424.
76.
Mikocka-Walus A, Ford AC, Drossman DA. Antidepressants in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:184–192.PubMed
77.
Ford AC, Wright-hughes A, Alderson SL et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:1773–1785.PubMed
78.
Iskandar HN, Cassell B, Kanuri N et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423–429.PubMedPubMedCentral
79.
Daghaghzadeh H, Naji F, Afshar H et al. Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: a double-blind controlled study. J Res Med Sci 2015;20:595–601.PubMedPubMedCentral
80.
Mikocka-Walus A, Prady SL, Pollok J, et al. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev 2019;4:CD012680.PubMed
81.
Dorn SD, Meek PD, Shah ND. Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin Gastroenterol Hepatol 2011;9:1078-1085.e1.PubMed
82.
Keefer L, Ko CW, Ford AC. AGA clinical practice update on management of chronic gastrointestinal pain in disorders of gut–brain interaction: expert review. Clin Gastroenterol Hepatol 2021;19:2481-2488.e1.PubMed
83.
Lin X, Lofland J, Zhang L et al. Opioid use in patients with inflammatory bowel disease. Crohn’s Colitis 2020;360:1–7.
84.
Dalal RS, Lund K, Zegers FD, Friedman S, Allegretti JR, Nørgård BM. Use of tramadol vs traditional opioids and adverse outcomes in patients with inflammatory bowel disease: a Danish nationwide cohort study. Inflamm Bowel Dis 2023;30:1121–1129.
85.
Sheehan JL, Jacob J, Berinstein EM et al. The relationship between opioid use and healthcare utilization in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2022;28:1904–1914.PubMedPubMedCentral
86.
Kaimakliotis P, Ramadugu A, Kang J et al. Targeted house staff intervention reduces opioid use without worsening patient-reported pain scores and improves outcomes among patients with IBD: the ‘IBD pain ladder.’ Int J Colorectal Dis 2021;36:1193–1200.PubMed
87.
Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT Registry. Am J Gastroenterol 2012;107:1409–1422.PubMedPubMedCentral
88.
Burr N, Smith C, West R, Hull M, Subramanian V. Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England. Clin Gastroenterol Hepatol 2018;16:534–541.PubMed
89.
Targownik L, Nugent Z, Singh H, Bugden S, Bernstein C. The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis. Am J Gastroenterol 2014;109:1613–1620.PubMed
90.
Farmer AD, Gallagher J, Bruckner-Holt C, Aziz Q. Narcotic bowel syndrome. Lancet. Gastroenterol Hepatol 2017;2:361–368.
91.
92.
93.
Dalal RS, Palchaudhuri S, Snider CK et al. A multimodal intervention using nonopioid analgesics is associated with reduced intravenous opioid exposure among hospitalized patients with inflammatory bowel diseases. Am J Gastroenterol 2020;115:1474–1485.PubMed
94.
Hsu C, Ghannoum M, Cominelli F, Di Martino L. Mycobiome and inflammatory bowel disease: role in disease pathogenesis, current approaches and novel nutritional-based therapies. Inflamm Bowel Dis 2023;29:470–479.PubMed
95.
Nitzan O, Elias M, Peretz A, Saliba W. 2016 Inflammatory Bowel Disease: global view Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016;22:1078–1087.PubMedPubMedCentral
96.
Emile SH, Horesh N, Freund MR et al. A systematic review and meta-analysis of randomized clinical trials on the prevention and treatment of pouchitis after ileoanal pouch anastomosis. J Gastrointest Surg 2023;27:2650–2660.PubMed
97.
Fan K, Eslick GD, Nair PM et al. Human intestinal spirochetosis, irritable bowel syndrome, and colonic polyps: a systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:1222–1234.PubMedPubMedCentral
98.
Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22–32.PubMed
99.
100.
Tocia C, Dumitru IM, Alexandrescu L, Petcu LC, Dumitru E. Does rifaximin offer any promise in Crohn’s disease in remission and concurrent irritable bowel syndrome-like symptoms? Medicine (Baltimore) 2021;100:1–7.
101.
Su GL, Ko CW, Bercik P et al. CLINICAL PRACTICE GUIDELINES AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology 2020;159:697–705.PubMed
102.
Ford AC, Quigley EMM, Harris LA, Lacy BE, Moayyedi P. Systematic review with meta-analysis : the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:1044–1060.PubMed
103.
Goodoory VC, Khasawneh M, Black CJ, Quigley EMM, Moayyedi P, Ford AC. Efficacy of probiotics in irritable bowel syndrome: systematic. Gastroenterology 2023;165:1206–1218.PubMed
104.
Selvamani S, Mehta V, Ali H et al. Saudi Journal of Biological Sciences efficacy of probiotics-based interventions as therapy for inflammatory bowel disease: a recent update. Saudi J Biol Sci 2022;29:3546–3567.PubMedPubMedCentral
105.
Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004;38:67–69.
106.
107.
Bogale K, Raup-Konsavage W, Dalessio S, Vrana K, Coates MD. Cannabis and cannabis derivatives for abdominal pain management in inflammatory bowel disease. Med Cannabis Cannabinoids 2021;4:97–106.PubMedPubMedCentral
108.
Pandey S, Kashif S, Youssef M et al. Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy. Complement Ther Med 2020;48:102242.PubMed
109.
Desai P, Mbachi C, Vohra I, et al. Association between cannabis use and healthcare utilization in patients with irritable bowel syndrome: a retrospective cohort study. Cureus 2020;12:e8008.PubMedPubMedCentral
110.
Patel RS, Goyal H, Satodiya R, Tankersley WE. Relationship of cannabis use disorder and irritable bowel syndrome (IBS): an analysis of 6.8 million hospitalizations in the United States. Subst Use Misuse 2020;55:281–290.PubMed
111.
Wynne J, Kozuch P. Medical marijuana for inflammatory bowel disease: the highs and lows. Scand J Gastroenterol 2022;57:197–205.PubMed
112.
Kienzl M, Storr M, Schicho R. Cannabinoids and opioids in the treatment of inflammatory bowel diseases. Clin Transl Gastroenterol 2020;11:e00120.PubMedPubMedCentral
113.
Doeve BH, Van De Meeberg MM, Van Schaik FDM, Fidder HH. A systematic review with meta-analysis of the efficacy of cannabis and cannabinoids for inflammatory bowel disease: what can we learn from randomized and nonrandomized studies? J Clin Gastroenterol 2021;55:798–809.PubMed
114.
Nduma BN, Mofor KA, Tatang J, Ekhator C, Ambe S, Fonkem E. The use of cannabinoids in the treatment of inflammatory bowel disease (IBD): a review of the literature. Cureus 2023;15:e36148.PubMedPubMedCentral
115.
Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn’s disease, a randomised controlled trial. J Crohn’s Colitis 2021;15:1799–1806.
116.
Naftali T, Schleider LBL, Benjaminov FS, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: a randomized controlled trial. PLoS ONE 2021;16:1–13.
117.
Ishida JH, Wong PO, Cohen BE, Vali M, Steigerwald S, Keyhani S. Substitution of marijuana for opioids in a national survey of US adults. PLoS ONE 2019;14:1–8.
118.
Dalal RS, Palchaudhuri S, Snider CK, Lewis JD, Mehta SJ, Lichtenstein GR. Preadmission cannabis use is positively correlated with inpatient opioid dose exposure in hospitalized patients with inflammatory bowel diseases. Inflamm Bowel Dis 2021;27:500–506.PubMed
119.
Glickman D, Dalessio S, Raup-Konsavage WM, Vrana KE, Coates MD. The impact of cannabis use on clinical outcomes in inflammatory bowel disease: a population-based longitudinal cohort study. Inflamm Bowel Dis 2023;30:1–7.
120.
Greywoode R, Cunningham C, Hollins M, Aroniadis O. Medical cannabis use patterns and adverse effects in inflammatory bowel disease. J Clin Gastroenterol 2023;57:824–829.PubMedPubMedCentral
121.
Meier MH, Caspi A, R Knodt A et al. Long-term cannabis use and cognitive reserves and hippocampal volume in midlife. Am J Psychiatry 2022;179:362–374.PubMedPubMedCentral
122.
Lovell ME, Akhurst J, Padgett C, Garry MI, Matthews A. Cognitive outcomes associated with long-term, regular, recreational cannabis use in adults: a meta-analysis. Exp Clin Psychopharmacol 2020;28:471–494.PubMed
123.
Velez-Santiago A, Alvarez-Torres E, Martinez-Rodriguez R et al. A survey of cannabis use among patients with inflammatory bowel disease (IBD). Int J Environ Res Public Health 2023;20:5129.PubMedPubMedCentral
124.
Buffone F, Tarantino AG, Belloni F et al. Effectiveness of osteopathic manipulative treatment in adults with irritable bowel syndrome: a systematic review and meta-analysis. Healthcare 2023;11:2442.PubMedPubMedCentral
125.
Espi-Lopez GV, Ingles M, Soliva-Cazaban I, Serra-Ano P. Effect of the soft-tissue techniques in the quality of life in patients with Crohn’s disease. Medicine (Baltimore) 2018; 97: el3811.
Metadata
Title
Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians
Authors
Natasha Klemm
Sarvee Moosavi
Publication date
13-11-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08716-y

Other articles of this Issue 12/2024

Neoplastic Pseudocirrhosis Pathophysiological Deepening

Hepatic Amyloidosis Without Hepatomegaly

Prostatic Adenocarcinoma Taking an Unusual Route: Rare Case of Pancreatic Metastasis

Comparing Environmental Risk Factors at Diagnosis in Faroese and Danish Patients with Inflammatory Bowel Disease

Predicting Portal Pressure Gradient in Patients with Decompensated Cirrhosis: A Non-invasive Deep Learning Model

Retirement of Dr. Denis McCarthy from the Editorial Board

  • Editorial

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video
Image Credits